𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Production of granulocytic colony-stimulating factor in patients with chronic myeloleukemia

✍ Scribed by M. Ya. Lisovskii; G. Yu. Miterev; N. D. Khoroshko; V. G. Savchenko

Publisher
Springer US
Year
1998
Tongue
English
Weight
293 KB
Volume
126
Category
Article
ISSN
0007-4888

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in cytokine production during th
Changes in cytokine production during therapy with Granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B
✍ Julio Martín; Juan A. Quiroga; Orencio Bosch; Dr. Vicente Carreño 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 584 KB

Recombinant human granulocyte-macrophage colony-stimulating factor therapy significantly reduces serum hepatitis B virus DNA levels, associated with increased 2',5'-oligoadenylate synthetase activity in cultured mononuclear cells of patients with chronic hepatitis B. To assess changes in immune func

Serum granulocyte colony-stimulating fac
Serum granulocyte colony-stimulating factor in patients with repeated infections
✍ Mutsumi Kawakami; Hisashi Tsutsumi; Toshiro Kumakawa; Makiko Hirai; Shinichiro K 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 2 views

We have already reported significant elevation of serum granulocyte colony-stimulating factor (G-CSF) in the acute phase of infection. In this study, we compared the responses to infection between patients with frequently repeated infection (repeaters) and others (nonrepeaters). We examined the clin

Granulocyte–colony-stimulating factor (f
Granulocyte–colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
✍ Alfonso Quintas-Cardama; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Maner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract ## BACKGROUND Imatinib mesylate administration has become standard treatment for patients with chronic myelogenous leukemia (CML). Although the safety profile of imatinib is favorable, Grade ≥ 3 neutropenia (according to the National Cancer Institute Common Toxicity Criteria) occurs in